Gilead Sciences Statistics
Share Statistics
Gilead Sciences has 1.25B
shares outstanding. The number of shares has increased by -0.04%
in one year.
| Shares Outstanding | 1.25B |
| Shares Change (YoY) | -0.04% |
| Shares Change (QoQ) | -0.07% |
| Owned by Institutions (%) | 84.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 100 |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 20.08M, so 1.61% of the outstanding
shares have been sold short.
| Short Interest | 20.08M |
| Short % of Shares Out | 1.61% |
| Short % of Float | 1.61% |
| Short Ratio (days to cover) | 1.89 |
Valuation Ratios
The PE ratio is 239.97 and the forward
PE ratio is 11.67.
Gilead Sciences's PEG ratio is
-2.62.
| PE Ratio | 239.97 |
| Forward PE | 11.67 |
| PS Ratio | 4.01 |
| Forward PS | 3.7 |
| PB Ratio | 5.96 |
| P/FCF Ratio | 11.18 |
| PEG Ratio | -2.62 |
Financial Ratio HistoryEnterprise Valuation
Gilead Sciences has an Enterprise Value (EV) of 131.91B.
| EV / Sales | 4.59 |
| EV / EBITDA | 29.75 |
| EV / EBIT | 12.18 |
| EV / FCF | 12.8 |
Financial Position
The company has a current ratio of 1.6,
with a Debt / Equity ratio of 1.38.
| Current Ratio | 1.6 |
| Quick Ratio | 1.45 |
| Debt / Equity | 1.38 |
| Debt / EBITDA | 6.02 |
| Debt / FCF | 2.59 |
| Interest Coverage | 1.7 |
Financial Efficiency
Return on Equity is 2.48% and Return on Invested Capital is 2.36%.
| Return on Equity | 2.48% |
| Return on Assets | 0.81% |
| Return on Invested Capital | 2.36% |
| Revenue Per Employee | $1,633,750 |
| Profits Per Employee | $27,272.73 |
| Employee Count | 17,600 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 3.66 |
Taxes
| Income Tax | 211M |
| Effective Tax Rate | 30.58% |
Stock Price Statistics
The stock price has increased by 52.29% in the
last 52 weeks. The beta is 0.28, so Gilead Sciences's
price volatility has been higher than the market average.
| Beta | 0.28 |
| 52-Week Price Change | 52.29% |
| 50-Day Moving Average | 108.18 |
| 200-Day Moving Average | 93.1 |
| Relative Strength Index (RSI) | 36.39 |
| Average Volume (20 Days) | 9,726,239 |
Income Statement
In the last 12 months, Gilead Sciences had revenue of 28.75B
and earned 480M
in profits. Earnings per share was 0.38.
| Revenue | 28.75B |
| Gross Profit | 22.5B |
| Operating Income | 1.66B |
| Net Income | 480M |
| EBITDA | 4.43B |
| EBIT | 1.67B |
| Earnings Per Share (EPS) | 0.38 |
Full Income StatementBalance Sheet
The company has 9.99B in cash and 26.71B in
debt, giving a net cash position of -16.72B.
| Cash & Cash Equivalents | 9.99B |
| Total Debt | 26.71B |
| Net Cash | -16.72B |
| Retained Earnings | 11.5B |
| Total Assets | 56.43B |
| Working Capital | 3.75B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 10.83B
and capital expenditures -523M, giving a free cash flow of 10.3B.
| Operating Cash Flow | 10.83B |
| Capital Expenditures | -523M |
| Free Cash Flow | 10.3B |
| FCF Per Share | 8.26 |
Full Cash Flow StatementMargins
Gross margin is 78.26%, with operating and profit margins of 5.78% and 1.67%.
| Gross Margin | 78.26% |
| Operating Margin | 5.78% |
| Pretax Margin | 2.4% |
| Profit Margin | 1.67% |
| EBITDA Margin | 15.42% |
| EBIT Margin | 5.78% |
| FCF Margin | 35.84% |
Dividends & Yields
GILD pays an annual dividend of $3.89,
which amounts to a dividend yield of 3.16%.
| Dividend Per Share | $3.89 |
| Dividend Yield | 3.16% |
| Dividend Growth (YoY) | 2.6% |
| Payout Ratio | 50.26% |
| Earnings Yield | 0.42% |
| FCF Yield | 8.95% |
Dividend DetailsAnalyst Forecast
The average price target for GILD is $110,
which is 11.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $110 |
| Price Target Difference | 11.8% |
| Analyst Consensus | Buy |
| Analyst Count | 23 |
Stock ForecastsStock Splits
The last stock split was on Jan 28, 2013. It was a
forward
split with a ratio of 2:1.
| Last Split Date | Jan 28, 2013 |
| Split Type | forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | 3.12 |
| Piotroski F-Score | 9 |
